Literature DB >> 9337065

Autologous stem cell infusion for acute myeloblastic leukemia in an HIV-1 carrier.

E Schneider1, M Lambermont, J P Van Vooren, G Bastin, W Feremans, A Kentos, F Lemoine, C Liesnard, M L Delforge, L Crenier, P Capel, C M Farber.   

Abstract

We present the case of an asymptomatic HIV carrier, who presented with acute myeloblastic leukemia in third relapse and successfully underwent autologous stem cell transplantation as a rescue treatment. This observation supports the conclusion that tolerance of autologous bone marrow or stem cell transplant in patients with HIV may correlate with a low viral burden and relatively good immune function.

Entities:  

Mesh:

Year:  1997        PMID: 9337065     DOI: 10.1038/sj.bmt.1700930

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Hematopoietic stem cell transplantation for HIV cure.

Authors:  Daniel R Kuritzkes
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.

Authors:  Christine Johnston; Robert Harrington; Rupali Jain; Joshua Schiffer; Hans-Peter Kiem; Ann Woolfrey
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-08       Impact factor: 5.742

3.  Acute myelogenous leukemia in a child with HIV infection.

Authors:  Milind S Tullu; Nitin B Date; Radha G Ghildiyal; Charusmita J Modi
Journal:  Eur J Pediatr       Date:  2009-10-03       Impact factor: 3.183

4.  Successful unrelated bone marrow transplantation for a human immunodeficiency virus type-1-seropositive acute myelogenous leukemia patient following HAART.

Authors:  Yoko Oka; Haruko Tashiro; Mitsuho Mizutani-Noguchi; Ichiro Koga; Toshihiko Sugao; Ryosuke Shirasaki; Toshiyuki Miura; Nobu Akiyama; Kazuo Kawasugi; Shin Fujimori; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2009-12-25       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.